We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
RETEVMO Eli Lilly Australia Pty Ltd
Product name
RETEVMO
Sponsor
Accepted date
Nov-2024
Active ingredients
selpercatinib
Proposed indication
RETEVMO is for the treatment of adult and adolescent (12 years of age and older) patients with medullary thyroid cancer that has an abnormnal version of the RET gene that has metastasised (spread) beyond the thyroid.
Application type
C (new indication)
Publication date
Nov-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.